Elanco Animal Health (NYSE:ELAN) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Elanco Animal Health (NYSE:ELAN) posted its quarterly earnings data on Tuesday. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01), Zacks reports. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.08 EPS.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $10.51 on Tuesday. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health has a twelve month low of $10.65 and a twelve month high of $18.80. The company has a market capitalization of $5.20 billion, a PE ratio of 26.26, a P/E/G ratio of 2.50 and a beta of 1.42. The firm has a fifty day simple moving average of $11.78 and a two-hundred day simple moving average of $13.09.

Analyst Ratings Changes

ELAN has been the subject of several recent research reports. Leerink Partners assumed coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target for the company. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Morgan Stanley lowered their target price on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 29th. Stifel Nicolaus lowered their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Barclays boosted their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $16.00.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.